Provided by Tiger Trade Technology Pte. Ltd.

Geron

1.47
-0.0800-5.16%
Volume:8.06M
Turnover:11.81M
Market Cap:938.38M
PE:-11.74
High:1.53
Open:1.53
Low:1.44
Close:1.55
52wk High:2.01
52wk Low:1.04
Shares:638.36M
Float Shares:534.08M
Volume Ratio:1.12
T/O Rate:1.51%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1252
EPS(LYR):-0.1252
ROE:-32.99%
ROA:-5.53%
PB:4.15
PE(LYR):-11.74

Loading ...

Investor Says He 'Doubled' His Savings After Using ChatGPT in Stock Research – Shares Top 5 Stock Picks

Benzinga_recent_news
·
Dec 19, 2025

Geron Corp - Begins Strategic Restructuring Plan - SEC Filing

THOMSON REUTERS
·
Dec 17, 2025

Geron Corporation Announces Workforce Reduction and $18 Million Restructuring Charge

Reuters
·
Dec 17, 2025

Geron Shares up 2.3% Premarket; Co Announces Strategic Restructuring Plan to Reduce Workforce by One-Third

THOMSON REUTERS
·
Dec 11, 2025

BRIEF-Geron Corporation Announces Strategic Restructuring Plan To Position The Company For Long-Term Value Creation

Reuters
·
Dec 11, 2025

Geron Corporation Cuts Workforce by One-Third in Strategic Restructuring

Reuters
·
Dec 11, 2025

Geron Corp - 2026 Operating Expenses Expected to Be Less Than 2025

THOMSON REUTERS
·
Dec 11, 2025

Geron Corp - Restructuring Plan to Reduce Workforce by One-Third

THOMSON REUTERS
·
Dec 11, 2025

Geron Corp - to Incur Cash-Based Restructuring Charges

THOMSON REUTERS
·
Dec 11, 2025

Geron Corp: Reduction in Geron's Current Workforce of About 260 Employees

THOMSON REUTERS
·
Dec 11, 2025

Geron Corp: Restructuring Plan Is Expected to Be Substantially Complete in Q1 of 2026

THOMSON REUTERS
·
Dec 11, 2025

Press Release: Geron Corporation Announces Strategic Restructuring Plan to Position the Company for Long-Term Value Creation

Dow Jones
·
Dec 11, 2025

Geron Corporation Reports on IL-8 and TNF-Alpha Correlation with Survival in Myelofibrosis Patients Treated with Imetelstat

Reuters
·
Dec 08, 2025

Geron Corporation Releases Phase 1b Trial Results on Imetelstat Plus Ruxolitinib for Myelofibrosis

Reuters
·
Dec 08, 2025

Geron Corporation publishes analysis on imetelstat treatment-emergent cytopenias and clinical response in lower-risk myelodysplastic syndromes

Reuters
·
Dec 08, 2025

Geron Unveils New Data Showing RYTELO Improves Outcomes in Lower-Risk MDS

Reuters
·
Dec 08, 2025

Geron Q3 EPS USD -0.03

Reuters
·
Nov 20, 2025

Wedbush Cuts Price Target on Geron to $5 From $6, Keeps Outperform Rating

MT Newswires Live
·
Nov 06, 2025

Stock Track | Geron Soars 9.17% Pre-Market Following Q3 Earnings and Positive Analyst Outlook

Stock Track
·
Nov 06, 2025

Stock Track | Geron (GERN) Surges 9.17% in Pre-market Following Positive Analyst Outlook Despite Mixed Q3 Results

Stock Track
·
Nov 06, 2025